ATOPIC DERMATITIS

This study follows patients with moderate-to-severe atopic dermatitis (eczema) who participated in earlier trials of afimkibart. It aims to understand the long-term safety and effectiveness of continued treatment. The study will track side effects and measure improvements in skin…

This study is testing whether children aged 1-17 who have their atopic dermatitis (eczema) well-controlled with the drug dupilumab can safely reduce their dose or stop taking it altogether. Participants will be randomly assigned to either continue their standard dose, take a lowe…

This program provides eligible patients with access to the drug upadacitinib for conditions like Crohn's disease, ulcerative colitis, and atopic dermatitis before it is officially approved in their country. A doctor must determine if the potential benefits for an individual patie…

This study aims to observe how well the drug dupilumab controls eczema and improves quality of life over two years in real-world settings. It will follow 900 patients in Germany, aged 6 and older, who are already starting this treatment. Researchers will track symptoms, side effe…

This study is testing a new laser device called PALLAS for treating skin conditions that often improve with UV light, including vitiligo, psoriasis, alopecia areata, and eczema. About 50 participants will receive targeted UVB laser treatments twice a week for up to three months. …

This is an early-stage study to check the safety and basic effects of a new drug called BBT001. It will first test single doses in healthy volunteers, then test repeated doses in adults with moderate to severe atopic dermatitis (eczema). The main goal is to see how well people to…

This study is testing a new oral medication, KT-621, for people with moderate to severe atopic dermatitis (eczema). For 16 weeks, some participants will receive the drug while others get a placebo, followed by a year where everyone can receive the active treatment. The main goals…

This study is testing whether adults with atopic eczema (atopic dermatitis) that is already well-controlled can safely take their dupilumab medication less often. Researchers will randomly assign 216 participants to receive their standard injection every 2 weeks, or to try extend…

This study is testing a new oral medication called soquelitinib for adults with moderate to severe eczema (atopic dermatitis). About 200 participants will take either the drug or a placebo pill daily for 12 weeks to see if it safely reduces skin inflammation and itching. Doctors …

This study is testing if a daily pill called Abrocitinib can help control eczema (atopic dermatitis) and patchy hair loss (alopecia areata) in people with Down Syndrome. It will enroll 56 participants aged 12 and older. The goal is to see if the treatment is safe and effective at…

This trial is testing whether an injectable drug called tralokinumab, when used with standard steroid creams, is safe and effective for controlling moderate-to-severe eczema in children and infants. It involves about 195 participants, from 6 months to under 12 years old, who have…

This study is testing a new drug called Afimkibart for people with moderate to severe eczema (atopic dermatitis). About 160 participants will receive either the drug or a placebo to see if it safely reduces skin inflammation and itching. The main goal is to see if the drug improv…

This study is testing whether following a healthy, balanced diet can help control eczema and related allergies. It will involve 110 adults in Singapore with mild-to-moderate eczema who will follow a specific meal plan for two months. Researchers will check if this diet improves s…

This study is testing if baricitinib, a drug used for other immune conditions, is safe for people with Job syndrome who also have lupus-like disease or a severe skin rash (atopic dermatitis). It will enroll about 20 participants aged 12 and older. The main goal is to check for si…

This study aims to see how well the approved drug nemolizumab works for people with moderate-to-severe eczema (atopic dermatitis) in real-world clinic settings. It will follow about 1000 adolescents and adults for up to a year, tracking their skin condition, itch, sleep, and pain…

This study is testing an investigational drug called IBI356 to see if it can reduce the rash and severe itching of moderate to severe atopic dermatitis (eczema). About 403 adult participants will be randomly assigned to receive either IBI356 or a placebo to compare effectiveness …

This is the first time a new drug called BGB-45035 is being tested in people. The main goal is to check if it is safe and how the body processes it. The study will first give the drug to healthy volunteers at different doses. Later, a small group of adults with itchy skin conditi…

This study is testing a cream called ruxolitinib to see if it safely reduces the severity and itch of moderate eczema in children and adolescents aged 6 to 18. It is for kids whose eczema hasn't responded well enough to standard topical treatments like steroid creams. The trial w…

This study aims to see which of two existing drugs works better and is safer for controlling moderate to severe eczema in children aged 2 to 12. About 675 children worldwide will take either a daily pill (upadacitinib) or receive injections every few weeks (dupilumab) for up to t…

This study is testing whether an oral medication called ICP-332 can effectively control moderate to severe atopic dermatitis (eczema) in adults. The trial will enroll 552 participants whose eczema hasn't responded well to standard topical treatments. Participants will receive eit…

This study is testing a cream called tapinarof to see if it is safe and effective for treating eczema in babies and toddlers aged 3 months to under 2 years. About 180 children will use the cream or a placebo for 8 weeks, followed by an open period where all can receive the active…

This small, early-stage study is testing if an oral medication called roflumilast can help control moderate-to-severe eczema (atopic dermatitis). For 12 weeks, 36 participants aged 12 and older will take the pill daily. Researchers will measure changes in skin rash, itch, and sle…

This study tests whether a pill called upadacitinib can help adults with moderate-to-severe eczema who didn't get enough relief from their current injectable medication, dupilumab. About 200 participants worldwide will take either the pill or continue injections for 32 weeks to s…

This study is testing whether a new injectable drug called IBI3002 can safely reduce the severity of moderate to severe atopic dermatitis (eczema). About 120 adults with eczema that hasn't responded well to creams will receive either IBI3002, an approved drug (dupilumab), or a pl…

This study is testing whether a new oral drug called ZL-82 can help control moderate to severe atopic dermatitis (eczema) in adults. About 111 participants will take either ZL-82 or a placebo pill daily for 16 weeks to see if it reduces the severity of their skin rash and itching…

This study is testing how well the injectable medication lebrikizumab works for people with moderate eczema covering 10-25% of their body who experience severe daily itching. About 200 adults and teenagers will receive the medication for 6 months to see if it reduces their eczema…

This early-stage study is testing a new injectable medication called BxC-I17e for adults with moderate-to-severe atopic dermatitis (eczema). Researchers will give 45 participants either the drug or a placebo to check for side effects and see if it helps reduce skin symptoms. The …

This study is testing a new drug called IMG-007 to see if it can reduce the severity of eczema and is safe for adults with moderate-to-severe cases. It will compare different doses of the drug against a placebo (an inactive substance) in about 220 people over 52 weeks. The goal i…

This is the first time a new drug called PF-07832837 is being tested in people. The main goal is to see if it is safe and how the body handles it. The study will involve both healthy volunteers and people with moderate to severe atopic dermatitis (eczema) to check for side effect…

This two-year study aims to understand the long-term safety and effectiveness of an oral liquid medication called abrocitinib for children aged 2 and older with moderate-to-severe eczema (atopic dermatitis). It will enroll about 500 children globally, including some who have take…

This study aims to see how well and safely the oral medication abrocitinib works for adults with moderate-to-severe eczema in real-world doctor's offices, not just controlled trials. About 183 participants will take the pill daily for up to 24 months while doctors track their ski…

This study is testing an investigational drug called FB825, given as five injections under the skin, to see if it can help control moderate-to-severe atopic dermatitis (eczema). It will involve about 90 adults whose eczema hasn't responded well to standard creams. The main goal i…

This study is testing two new injectable medicines (PF-07275315 and PF-07264660) for adults with moderate-to-severe atopic dermatitis (eczema) who haven't gotten enough relief from skin creams. Participants will receive either one of the study medicines or a placebo (inactive sho…

This study is observing how well the oral medication abrocitinib works for people with moderate-to-severe eczema (atopic dermatitis) in real-world clinics. It focuses on about 150 patients aged 12 and older who did not get enough relief or could not tolerate up to two previous bi…

This study is testing whether an experimental medication called GIA632 can help control moderate to severe eczema (atopic dermatitis). Researchers will compare GIA632 against a placebo in 84 adult participants over 16 weeks to see if it improves skin symptoms and is safe to use. …

This study aims to find out if an investigational drug called APG777 is safe and effective for long-term use in people with moderate-to-severe eczema (atopic dermatitis). It is open only to people who have already completed a previous study with APG777. The main goal is to monito…

This study is testing a new topical gel containing a specific strain of bacteria (Staphylococcus hominis A9) to see if it is safe and can help control eczema. It will enroll about 86 adults and adolescents with eczema who have a common 'bad' bacteria (Staphylococcus aureus) on th…

This study aims to understand how people in China actually use the eczema medication upadacitinib in everyday practice, outside of strict clinical trials. It will follow about 1000 adolescents and adults with moderate-to-severe eczema for approximately 12 months. Researchers will…

This study is testing several new medications for people with moderate to severe eczema (atopic dermatitis). Researchers will compare the experimental treatments against a placebo to see which works better at reducing skin inflammation and symptoms. The trial involves 224 partici…

This study is testing whether a new moisturizing cream called GX-03 can help control eczema symptoms better than a standard cream. About 100 adults with moderate to severe eczema will apply either GX-03 or a control cream twice daily for 8 weeks. Researchers will measure changes …

This is an early-stage study to check the safety of a new drug called BBT001 for people with moderate-to-severe eczema (atopic dermatitis). Researchers will give the drug to healthy volunteers and eczema patients in increasing doses to see how well it is tolerated and how it move…

This study is testing an investigational drug called galvokimig for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to standard creams. Researchers will compare several doses of the drug against a placebo to see which works best at reducing sk…

This study is testing whether an experimental drug called TRIV-509 helps adults with moderate to severe eczema. About 90 participants will receive either TRIV-509 or a placebo injection for 16 weeks, then switch to the other treatment. Researchers will measure skin improvement an…

This study is testing whether a spray containing a harmless skin bacteria (Roseomonas mucosa) mixed with ground cardamom seeds can help control eczema. About 120 people aged 2 and older with eczema will spray the solution on their skin 2-3 times a week for 14 weeks. Half will get…

This study is testing an investigational drug called ATI-045 to see if it can reduce the skin rash and severe itching of moderate-to-severe eczema (atopic dermatitis). About 96 adults who haven't gotten enough relief from standard creams will receive either the drug or a placebo …

This study is testing a new skin cream to see if it helps with dry, itchy skin conditions like eczema and psoriasis. Researchers will compare it to petroleum jelly, a common moisturizer, over 28 days. About 26 adults will apply the cream twice daily and have their skin checked we…

This study is checking if a medicine called dupilumab, already used for moderate-to-severe eczema, can also help improve anxiety and depression in people with this skin condition. It will observe about 184 patients from Gulf countries who are starting this treatment for 6 months.…

This study is testing whether a special moisturizer containing a probiotic (Lactobacillus reuteri) can help improve eczema symptoms in children. Researchers will enroll 40 kids, aged 6 months to 12 years, with moderate eczema. They will apply the cream for 8 weeks to see if it re…

This is an observational study aiming to understand why food allergies develop and how they progress over time. Researchers will follow up to 1,800 participants, including people with food allergies, their relatives, and healthy volunteers, for many years. The study involves coll…

This study aims to understand why some people with eczema and related allergies like asthma and food allergies go into remission while others do not. Researchers will follow 1,000 participants, including healthy people, over time to collect health and lifestyle data. The goal is …

This study is testing whether a short, hands-on demonstration helps people with eczema use the right amount of prescription cream. Researchers will compare patients who get the special demo to those who receive standard written and verbal instructions. The goal is to see if bette…

This study looks at pregnancy outcomes for women with eczema who used ruxolitinib cream during pregnancy compared to those who used standard steroid creams. Researchers will analyze health insurance claims data from over 5,600 women to check for birth defects and other pregnancy …

This study aims to understand how the body's chemical processes (metabolism) relate to immune system problems that cause skin conditions like eczema and psoriasis. Researchers will collect small skin samples and blood from 300 participants, including people with these conditions …

This study aims to understand how doctors in France manage adults with moderate-to-severe atopic dermatitis (eczema) who are eligible for or already receiving systemic (whole-body) medications. It will observe 600 patients in their regular care settings for one year, tracking whi…

This study aims to track the long-term safety and effectiveness of eczema treatments in teenagers. It will follow about 1,500 adolescents aged 12-15 with moderate to severe eczema who are starting a new medication. The goal is to collect real-world information to help doctors, pa…

This study aims to find out how often adult atopic dermatitis (eczema) affects the eyelids, a common but poorly understood problem. Researchers will observe 550 adult patients with eczema in France to measure eyelid involvement and look for links with allergies, other eye conditi…

This study is creating a registry to collect information from young people with eczema who are using or starting systemic (whole-body) treatments. The goal is to build a database that helps researchers understand which treatments work best, monitor safety, and quickly connect pat…

This early-stage study aims to understand how a new potential drug for atopic dermatitis (eczema), called CKD-706, behaves in the body compared to two versions of an existing drug, Dupixent. It involves 519 healthy adult volunteers who will receive a single dose. Researchers will…

This study aims to collect blood, urine, and skin samples from adults with specific skin conditions like cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The purpose is to build a collection of samples for researchers to study. By analyzing these samples, scientists hope …

This study aims to understand if using ruxolitinib cream for mild to moderate eczema during pregnancy affects the baby's health. Researchers will compare pregnancy outcomes and infant health between women who used the cream and those who did not. The study is observational, meani…

This study aims to understand if the eczema medication dupilumab works the same way in people of different ethnic backgrounds. Researchers will compare the immune system responses of Caucasian, Asian, and African American patients with moderate-to-severe eczema over 16 weeks of t…

This study aims to understand how eczema (atopic dermatitis) and food allergies might be connected biologically. Researchers will collect blood and skin samples from 200 people with different combinations of these conditions and healthy volunteers. The goal is to create a 'molecu…

This study aims to understand the community of tiny organisms (like bacteria and fungi) that live on human skin. Researchers will compare the skin microbes of healthy people to those with moderate-to-severe eczema (atopic dermatitis) and some rare immune disorders. By taking skin…

This study is creating a large registry of patients with conditions like eczema, psoriasis, and alopecia areata to track how treatments work in real-world settings. Researchers will follow 15,000 adults and children over time to understand treatment safety, effectiveness, and how…

This study aims to better understand chronic hand eczema and atopic dermatitis by observing and measuring skin changes over time. Researchers will compare adults with these conditions to healthy volunteers using non-invasive scans and tape strips to collect skin samples. The stud…

This study aims to understand how people with moderate-to-severe eczema (atopic dermatitis) respond to prescription treatments in everyday life, not in a controlled clinic. It will follow 1,000 patients aged 12 and older for five years across 10 countries, tracking which treatmen…

This study aims to understand if the eczema medication abrocitinib (CIBINQO) is safe for use during pregnancy. Researchers will follow 400 pregnant women with moderate-to-severe eczema—some taking the drug and some not—and track their babies' health through the first year of life…